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Activation of the TGFβ 
pathway impairs endothelial to 
haematopoietic transition
Özge Vargel1, Yang Zhang1,†, Kinga Kosim1, Kerstin Ganter1, Sophia Foehr2, 
Yannicka Mardenborough1, Maya Shvartsman1, Anton J. Enright3, Jeroen Krijgsveld2 & 
Christophe Lancrin1
The endothelial to haematopoietic transition (EHT) is a key developmental process where a drastic 
change of endothelial cell morphology leads to the formation of blood stem and progenitor cells during 
embryogenesis. As TGFβ signalling triggers a similar event during embryonic development called 
epithelial to mesenchymal transition (EMT), we hypothesised that TGFβ activity could play a similar role 
in EHT as well. We used the mouse embryonic stem cell differentiation system for in vitro recapitulation 
of EHT and performed gain and loss of function analyses of the TGFβ pathway. Quantitative proteomics 
analysis showed that TGFβ treatment during EHT increased the secretion of several proteins linked 
to the vascular lineage. Live cell imaging showed that TGFβ blocked the formation of round blood 
cells. Using gene expression profiling we demonstrated that the TGFβ signalling activation decreased 
haematopoietic genes expression and increased the transcription of endothelial and extracellular 
matrix genes as well as EMT markers. Finally we found that the expression of the transcription factor 
Sox17 was up-regulated upon TGFβ signalling activation and showed that its overexpression was 
enough to block blood cell formation. In conclusion we showed that triggering the TGFβ pathway does 
not enhance EHT as we hypothesised but instead impairs it.
Haematopoietic stem and progenitor cells (HSPC) arise during embryonic life through a process called endothe-
lial to haematopoietic transition (EHT)1–5. This is an evolutionary conserved embryonic process, which takes 
place in mammals and lower vertebrates such as fishes and frogs6. The EHT requires the loss of endothelial fea-
tures and acquisition of haematopoietic ones. Loss of cell-cell adhesion between endothelial cells is required to 
enable the release of the HSPC in the blood stream. Signalling pathways responsible for this process are not well 
characterized.
Epithelial cells can convert to another cell type called mesenchymal cell by a process called epithelial to mesen-
chymal transition (EMT). It was first observed in the primitive streak of chick embryos7. It was later demonstrated 
to be an important process in the formation of metastasis in cancers occurring in epithelial tissues8. EMT leads 
to the loss of cell-cell interaction and organisation of an epithelial cell layer. It involves major changes in adhesion 
properties, morphology and mobility. Interestingly, the endothelial cells can also undergo a specific form of EMT, 
the endothelial to mesenchymal transition (EndMT) by which endothelial cells become mesenchymal, acquiring 
morphological features compatible with cell mobility and migration9. It takes place during embryonic develop-
ment to enable the formation of endocardial cushions10 and can be involved in diseases such as the fibrodysplasia 
ossificans progressiva (FOP)11 and cerebral cavernous malformations12.
The transforming growth factor beta (TGFβ ) signalling pathway has been shown to induce EMT and 
EndMT8,9. The pathway consists of three main players: TGFβ ligands, cell membrane bound receptors and intra-
cellular effector molecules13. The signalling is initiated upon binding of a ligand on a homodimer of TGFβ recep-
tor type II (TGFBR2). This binding recruits a TGFβ receptor type I homodimer such as TGFBR1 (ALK5) to form 
all together a hetero-tetrameric complex while TGFBR2 phosphorylates the type I receptors. Phosphorylated type 
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I receptors become active and then phosphorylate and activate a group of receptor regulated SMAD (R-SMAD) 
proteins (SMAD2 and 3 for TGFBR1). The phosphorylated R-SMADs later form heterodimers with the common 
mediator SMAD proteins (SMAD4) and localize into the nucleus where they activate transcription of target 
genes. Another type of SMAD proteins, inhibitory SMAD (SMAD6 and 7), can block the phosphorylation of 
R-SMADs, which cuts off the down-stream relay of the signal13. TGFBR1 and SMAD3 are key players in the 
induction of EMT by activating the expression of the transcription factor SNAIL14.
Embryonic stem cell (ESC) differentiation model has been used extensively to study embryonic haematopoie-
sis and has been instrumental in our understanding of key events happening during formation of blood cells15. 
Haematopoietic progenitor cells (HPC) are also formed through the process of EHT in the ESC differentiation 
model16,17. We have used this system to test whether or not activation of TGFβ signalling enhances EHT like it 
does for EMT and EndMT. We used a wide range of methods from quantitative RT-PCR, quantitative proteomics 
analysis of the secretome, ESC differentiation, flow cytometry, live cell imaging and mRNA microarrays to study 
the impact of loss and gain of function of the TGFβ signalling on the formation of HPCs. Surprisingly, unlike the 
promoting effect of TGFβ in EMT and EndMT, we found that the TGFβ signalling inhibits EHT.
Results
TGFβ pathway related genes are expressed during EHT. Using the embryonic stem cell differen-
tiation system it is possible to recapitulate the first events of blood cell development taking place in the mouse 
embryo18. After isolating mesodermal Flk1+ containing Blast-Colony-Forming Cells (BL-CFC), common pre-
cursor of blood and endothelial cells19,20, from day 3–3.25 embryoid body (EB) differentiation and putting them 
in culture in presence of VEGF and IL6, we can follow the formation of blood cells from endothelial cells (EC). 
They differentiate into haematopoietic progenitor cells (HPC) via the formation of an intermediary stage called 
pre-haematopoietic progenitor cells (Pre-HPC). We isolated each population based on the expression of the 
endothelial marker VE-Cadherin (VE-Cad)21 and the haematopoietic marker CD4117 by flow cytometry after 
1.5 days of BL-CFC culture (Fig. 1A and Supplementary Fig. S1A): VE-Cad+CD41− (EC) expressing high level of 
endothelial genes (Cdh5, Kdr and Pecam1) but low level of blood genes (Runx1, Myb and Gata1), VE-Cad+CD41+ 
(Pre-HPC) co-expressing endothelial and haematopoietic genes and VE-Cad−CD41+ (HPC) expressing only 
haematopoietic genes (Supplementary Fig. S1B and S1C). To find out if any of these populations could respond to 
TGFβ signalling, we performed quantitative RT-PCR (q-RT-PCR) to detect 15 genes coding for proteins involved 
in the TGFβ signalling pathway: 4 receptors, 3 ligands and 8 SMADs (Fig. 1 and Supplementary Table S1). All 
these genes were transcribed in the EC population although Tgfb3 and Smad8 were expressed at a low level. 
The Pre-HPC population expressed many of these genes although there was a clear drop in expression levels for 
Acvrl1, Tgfbr2 and Tgfb2 that were even lower in HPC. All populations expressed the Smad genes and Tgfbr1; 
however Tgfbr2 and Acvrl1 were only detected in EC and Pre-HPC suggesting that these 2 populations were the 
most likely to respond to TGFβ signalling. This gene expression analysis indicated that the TGFβ signalling could 
play a role in EHT.
TGFβ2 treatment during BL-CFC culture increases the secretion of proteins linked with vascular 
development, extracellular matrix and cell mobility. Between day 1 and day 2 of BL-CFC culture, 
there is a clear increase of CD41+ blood precursors suggesting that endothelial to haematopoietic transition 
occurs during that time17. To get an insight into proteins involved in cellular communication, adhesion and 
migration occurring during EHT, we performed a secretome analysis of BL-CFC cells to detect the proteins 
secreted upon TGFβ pathway activation compared to control conditions. If the TGFβ signalling promotes EHT, 
we would expect the secretion of proteins linked to haematopoiesis. To test this hypothesis, we performed stable 
isotope labelling with amino acids in cell culture (SILAC) in combination with labelling with azidohomoalanine 
(AHA). AHA, an artificial amino-acid analogue of methionine permits the capture of newly synthesized proteins 
through click chemistry followed by mass spectrometry for protein identification22.
After 1 day of BL-CFC culture, cells were treated for 6 hours with TGFβ 211 or with the vehicle as a negative 
control in presence of AHA, ‘intermediate’ or ‘heavy’ isotopes of lysine and arginine. Supernatants from the 2 
conditions were harvested and pooled; AHA-containing proteins were isolated with click chemistry and sub-
jected to liquid chromatography tandem mass spectrometry (LC-MS/MS) (Fig. 2A). In the meantime the cells 
were harvested for flow cytometry analysis and examined for the expression of CD41 and VE-Cad markers. 
Surprisingly we noticed that the 6 hours TGFβ 2 treatment increased the frequency of EC (VE-Cad+CD41−) by 
4-fold compared to the non-treated condition whereas the frequency of HPC (VE-Cad−CD41+) was reduced by 
roughly 2-fold (Fig. 2B).
In the three biological replicates we could identify between 133 and 268 proteins newly synthesized dur-
ing the 6 hours pulse (Supplementary Table S2). The number of proteins with secreted evidence varied between 
80 and 100 (Supplementary Fig. S2A). Pairwise comparisons between these samples showed correlation values 
between 0.78 and 0.92 (Supplementary Fig. S2B). Fifty-six proteins were differentially expressed in all 3 replicates 
including 33 with secreted evidence. According to the STRING analysis tool23, the majority of these proteins had 
interactions between them (Fig. 2C). Interestingly, 85% of these secreted proteins had an increased expression 
after TGFβ 2 treatment (Fig. 2B and Supplementary Table S3). Among them DCBLD2 is important for angio-
genesis24; CX3CL1 (also known as Fractalkine) is a chemokine produced by endothelial cells25; COL5A1 is cru-
cial for cardiovascular development26; PLVAP helps to maintain vascular permeability of endothelial cells27 and 
MMP2 is a target of TGFβ signalling and an important player in EMT28,29. Gene ontology (GO) analysis indicated 
enrichment in proteins involved in cell migration, extracellular matrix organization and vasculature development 
(Supplementary Fig. S3). Although Csf130, a cytokine supporting macrophage growth, was detected, its expres-
sion was not up-regulated after TGFβ 2 treatment (Supplementary Table S2).
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Overall, this first series of experiments suggests that the TGFβ pathway does not enhance haematopoietic 
development. On the contrary, only 6 hours of TGFβ treatment was sufficient to increase clearly the frequency of 
the endothelial cells and the quantity of secreted proteins related with vascular development, extracellular matrix 
organisation and cell migration.
TGFβ pathway activation blocks EHT. Our previous experiments suggested an inhibitory effect of 
TGFβ on EHT. We sought to verify this by using a different assay. For this new analysis we focused on Pre-HPC 
(VE-Cad+CD41+). When these cells were isolated and put in culture most of them still had an endothelial cell 
morphology after 24 hours (Fig. 3A). One of the landmarks of blood cell formation is the change in morphology 
from flat and adherent to round and floating (Fig. 3A). We decided to choose this step of EHT as an ideal read-out 
to analyse the impact of TGFβ activity. In order to activate the TGFβ signalling pathway, we added TGFβ 2 into 
the culture medium. Since TGFBR1 activation has been shown to trigger EMT14 we chose to use SB43154231 to 
inhibit the pathway. As a control, we used normal culture medium with the same volume of vehicle (DMSO for 
SB431542) or without anything (Supplementary Fig. S4).
The cells were re-plated in haemogenic endothelium mix17 with either nothing, DMSO, SB431542 or TGFβ 2 
for 3 days. The time-lapse images were taken for 3 days every 15 minutes. The number of round cells during the 3 
days of culture was quantified by analysing the images with the CellProfiler software. The DMSO control was very 
similar to the control with nothing added (Fig. 3, Supplementary Videos S1&S2). However there was a profound 
difference between the cells treated with SB431542 or TGFβ 2. In presence of TGFβ 2, we could clearly see a drastic 
decrease of round cells’ number (Fig. 3 and Supplementary Video S3) while the treatment with SB431542 led to 
an increase in the number of round cells (Fig. 3 and Supplementary Video S4). In accordance to the microscopy 
data, the number of cells after TGFβ treatment decreased while the number of cells increased after SB431542 
addition (Fig. 3C). At the end of the culture, the cells were examined for VE-Cad and CD41 expression by flow 
Figure 1. TGFβ pathway related genes are expressed during in vitro EHT. (A) Experimental workflow 
used to generate the indicated 3 populations from ESC. (B) Expression of TGFβ receptor coding genes in 
EC, Pre-HPC and HPC populations. (C) Expression of TGFβ ligand coding genes in EC, Pre-HPC and HPC 
populations. (D) Expression of SMAD coding genes in EC, Pre-HPC and HPC populations. The box plots were 
generated from 3 independent experiments. For each plot, the top and bottom box edges correspond to the first 
and third quartiles. The black line inside the box represents the median. The top and bottom whisker lines mark 
the maximum and minimum values of the data set, respectively. The corresponding p-values were calculated 
with Student’s t-test (Supplementary Table S1).
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cytometry analysis. The cells were expected to be mostly HPC (VE-Cad−CD41+) with very few cells remaining 
Pre-HPC (VE-Cad+CD41+). This was what we observed for the conditions Medium only and DMSO (Fig. 3D,E). 
Figure 2. TGFβ treatment during BL-CFC culture favours the vascular lineage over the haematopoietic 
one. (A) Experimental workflow of the quantitative secretome analysis by LC-MS/MS. (B) Flow cytometry 
analysis of VE-Cad and CD41 expression after 6 hours of culture following the addition of TGFβ 2 compared 
to control condition. Upper panel shows one representative example of flow cytometry analysis while the 
bottom one shows a bar graph representing the average frequency of the EC (VE-Cad+CD41−) and HPC 
(VE-Cad−CD41+) populations from 3 independent experiments. The p-values were calculated with Student’s 
t-test (2 tails, type 3). EC population: **Control versus TGFβ 2 p-value = 0.004 (n = 3); HPC population: 
*Control versus TGFβ 2 p-value = 0.03 (n = 3). (C) Heatmap representing Log2 fold change (Log2 FC) of protein 
expression between TGFβ 2 treated and non-treated samples for all the proteins detected in the 3 biological 
replicates. Each column represents one independent secretome experiment. (D) STRING representation of a 
network involving the proteins detected in C. Nine proteins out of 33 were not part of the network. Different 
line colours represent the types of evidence for the association between proteins.
www.nature.com/scientificreports/
5Scientific RepoRts | 6:21518 | DOI: 10.1038/srep21518
Figure 3. TGFβ treatment blocks blood cell formation, reduces the frequency of haematopoietic cells and 
increases the frequency of endothelial cells. (A) Images of the haemogenic endothelium (HE) culture taken 
after 24, 48 and 60 hours in different conditions. The scale bar corresponds to 200 μ m. (B) Quantification of the 
number of round cells generated during time-lapse imaging in the 4 indicated conditions. Each value represents 
the mean of the number of round cells for 9 areas of the same well. Error bars represent standard deviation.  
(C) Bar graphs representing the average cell number of the 3 indicated conditions from 3 independent 
experiments. Error bars correspond to standard deviation. The p-values were calculated with Student’s t-test  
(2 tails, type 3). *DMSO versus TGFβ 2 p-value = 0.035 (n = 3); *SB431542 versus TGFβ 2 p-value = 0.03 
(n = 3). (D) Flow cytometry analysis of VE-Cad and CD41 expression after 3 days of culture following 
the addition of TGFβ 2 compared to control condition for one representative experiment. (E) Bar graphs 
representing the average frequency of the 2 indicated populations from 3 independent experiments. Error bars 
correspond to standard deviation. The p-values were calculated with Student’s t-test (2 tails, type 3). VE-Cad− 
CD41+ population p-values: **Medium only versus TGFβ 2 p-value = 0.004 (n = 3); **DMSO versus TGFβ 2 
p-value = 0.004 (n = 3); **SB431542 versus TGFβ 2 p-value = 0.0001 (n = 3). VE-Cad+ CD41− population 
p-values: **Medium only versus TGFβ 2 p-value = 0.00018 (n = 3); **DMSO versus TGFβ 2 p-value = 0.0011 
(n = 3); **SB431542 versus TGFβ 2 p-value = 0.0015 (n = 3).
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In the SB431542 condition, we noticed a slight increase of HPC frequency compared to controls. On the other 
hand we observed a very low frequency of HPC (around 7 times less than in the other 3 conditions) in the TGFβ 2 
treated samples suggesting that TGFβ 2 inhibits EHT. Moreover the majority of cells at the end of the culture have 
lost their Pre-HPC phenotype and adopted an EC phenotype (VE-Cad+ CD41−) instead (Fig. 3D,E). This FACS 
analysis was both consistent with the microscopy analysis and secretome analysis of Fig. 2.
To confirm the effect of SB431542 on EHT, we compared its activity to the over-expression of Smad7, another 
inhibitor of TGFBR132,33. We made an inducible cell line where GFP-Smad7 could be induced upon addition 
of doxycycline (dox) (Supplementary Fig. S5A & S5B). We first showed that SB431542 treatment and Smad7 
overexpression for 24 hours both decreased the frequency of endothelial cells by 2-fold in the BL-CFC assay 
(Supplementary Fig. S5C). This phenotype is in accordance with the increase of endothelial cells’ frequency 
observed after TGFβ 2 treatment in Fig. 2B.
When we tested the over-expression of Smad7 at the pre-HPC stage, we observed only a small increase in 
round cells’ number in presence of dox compared to the no dox control (Supplementary Fig. S5D). This suggests 
that the overexpression of Smad7 could not fully recapitulate SB431542 activity.
In conclusion, microscopy and flow cytometry data reinforced the notion that the TGFβ signalling does not 
enhance EHT. On the contrary, TGFβ activation resulted in almost no round cells but more flat and scattered 
VE-Cad+CD41− cells (Fig. 3 and Supplementary Video S3).
Gene expression profiling after activation and inhibition of the TGFβ signalling pathway con-
firms the inhibitory role of TGFβ in EHT. We performed mRNA microarray analysis of the 3 sets of cells: 
treated with DMSO (control), with SB431542 (inhibitor) and with TGFβ 2 (activator) (Fig. 4A, Supplementary 
Fig. S4 and Supplementary Table S4). Principal Component Analysis (PCA) showed clearly that the activator 
samples were very different than the other two. Control and inhibitor samples were clustering together indicating 
similar expression profile (Fig. 4A). Hierarchical clustering analysis with the top 250 differentially expressed 
genes confirmed the results of the PCA (Supplementary Fig. S6). This gene expression analysis was consistent 
with the flow cytometry data described previously where the biggest difference was between the cells treated with 
TGFβ 2 and the other conditions (Fig. 3).
Differential gene expression analysis between control and activator samples generated a list of over 2400 genes 
whose expression was changed by at least 2-fold between the 2 conditions (Supplementary Table S4). DAVID 
Gene ontology analysis34 showed that the activator treatment up-regulated the expression of genes linked to 
extracellular matrix, vasculature development and cell adhesion (Fig. 4B and Supplementary Table S5). These 
GO terms were the same as the ones we found for the secreted proteins in Supplementary Fig. S3. On the other 
hand, the down-regulated genes were associated to the GO terms cell cycle, immune response and inflammatory 
response (Fig. 4B). This strongly supported the notion of the inhibition of blood cell development in presence 
of TGFβ 2. Moreover the reduction of cell cycle related genes could be associated to the inhibitory effect on the 
cell cycle of the TGFBR1 activation35. This is consistent with the decreased cell number observed after TGFβ 2 
treatment (Fig. 3C).
The list of genes differentially expressed between control and inhibitor samples was much smaller. Upon TGFβ 
pathway inhibition there were only 62 up-regulated (> 2 fold) genes while 168 genes were down-regulated more 
than 2 fold compared to the control (Supplementary Table S4). This was consistent with the PCA and hierarchical 
clustering showing high expression similarities between them. Nonetheless, there were clear differences in the list 
of down-regulated genes in response to SB431542 treatment. These genes were related to vasculature develop-
ment, extracellular matrix and cell adhesion GO terms (Fig. 4C). Most of the down-regulated genes in presence 
of inhibitor were up-regulated in presence of TGFβ 2 (Fig. 4D).
We demonstrated in previous experiments a dramatic reduction of blood cell generation in presence of 
TGFβ 2. This was supported by a clear down-regulation of many important haematopoietic genes such as Runx1, 
a crucial regulator of EHT4,17, Spi1, a key transcription factor for the development of myeloid and lymphoid line-
ages36 and Gata1, an essential gene for the formation of red blood cells37 (Fig. 4E).
The previous microscopy analysis showed that activation of the TGFβ signalling led to a mesenchymal mor-
phology compatible with an EMT process. We found a set of up-regulated genes related to the GO terms of 
mesenchymal cell differentiation and mesenchyme development (Supplementary Table S5). To confirm this 
observation, we looked for EMT markers, Cdh2, Fst, Serpine1, Acta2, Twist1, Snai1 and Snai28. They were all 
up-regulated after TGFβ signalling activation compared to control (Fig. 4F). In contrast, the difference between 
inhibitor and control samples were very small reflecting the already low level of expression of these genes in 
normal conditions.
In the proteome analysis, we identified 33 proteins whose quantity in the extracellular space was changed 
upon TGFβ 2 treatment. The genes coding for these proteins belonged to the GO terms vasculature development, 
extracellular matrix and cell adhesion (Supplementary Fig. S3). We therefore looked for the genes coding for these 
proteins in the microarray data and found that 15 of them were clearly more expressed in presence of TGFβ 2, 
which is consistent with the change of protein quantity we found in our secretome experiment (Fig. 2C). Only 2 
of them (Fbn1 and Mmp2) were down-regulated after SB431542 treatment (Fig. 4G).
To confirm the microarrays results, we performed q-RT-PCR for a selection of 17 genes on cDNA from 
Control, SB431542 and TGFβ 2 conditions. We examined the expression of 6 genes related to the vascular lin-
eages: Cdh5, Pecam1, Bmp4, Col4a2, Fbn1 and Sox17. We found that they were all up-regulated upon TGFβ 2 
treatment confirming the microarray analysis (Fig. 5A and Supplementary Table S7).
We studied the expression of 6 haematopoietic genes, Itga2b, Itgb3, Runx1, Spi1, Itgam and Mpo. As expected 
most of these genes were down-regulated upon TGFβ 2 treatment (Fig. 5B). Only Itgb3 expression was not signif-
icantly different between DMSO and SB431542 conditions (Supplementary Table S7).
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Finally, we tested the expression of EMT genes Acta2, Cdh2, Serpine1, Snai1 and Snai2. Acta2, Cdh2 and 
Serpine1 were strongly up-regulated after TGFβ signalling activation whereas a very modest increase of Snai1 
(p-value = 0.01) and Snai2 (p-value = 0.046) expression was observed (Fig. 5C and Supplementary Table S7). We 
noticed a small but significant decrease for Acta2 and Serpine1 expression after SB431542 treatment (Fig. 5C and 
Supplementary Table S7).
Figure 4. mRNA microarray analysis reveals the impact of TGFβ signalling activation or inhibition at 
the transcriptional level. (A) Principal component analysis of the samples. (B) Functional annotation for 
the “Activator versus Control” contrast. The log2 p-value was plotted for each GO term. The number of genes 
per group is also indicated. (C) Functional annotation for the “Inhibitor versus Control” contrast. The log2 
p-value was plotted for each GO term. The number of genes per group is also indicated. (D) Heatmap of Log2 
FC of genes from the vasculature development (left) and extracellular matrix (right) GO terms. Log2 FC values 
obtained from Activator versus Control (ActvsCont) contrast were compared to the ones from Inhibitor versus 
Control (InhvsCont) contrast. (E) Heatmap of Log2 FC of haematopoietic genes. (F) Heatmap of Log2 FC of 
EMT genes. (G) Heatmap of Log2 FC of candidate genes corresponding to detected proteins in Fig. 2.
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In conclusion, our gene expression analysis confirmed the inhibitory effect of TGFβ on the EHT. TGFβ sig-
nalling activation reduced hematopoietic gene expression and increased the expression of endothelial genes and 
EMT markers.
TGFβ pathway related genes are expressed during EHT in the Aorta Gonad Mesonephros 
region. Next we decided to study the role of TGFβ pathway in the EHT taking place in the Aorta Gonad 
Mesonephros (AGM) region, one of the main sites of blood cell formation in the mouse embryo6. We sorted 
the EC (VE-Cad+CD41−), Pre-HPC (VE-Cad+CD41+) and HPC (VE-Cad−CD41+Kit+) populations from E11 
AGM. As for the in vitro EHT populations, EC express high level of endothelial genes (Cdh5, Kdr and Pecam1) 
but low level of blood genes (Runx1, Myb and Gata1), Pre-HPC co-express endothelial and haematopoietic genes 
and HPC express only haematopoietic genes (Supplementary Fig. S7). We performed PCR for the TGFβ path-
way related genes (Fig. 6 and Supplementary Table S8) and found an expression pattern very similar to the ones 
observed for the in vitro generated populations (Fig. 1). The EC population expressed all the tested TGFβ pathway 
genes while they were gradually down-regulated during EHT at the exception of Tgfb1, Smad2 and Smad3. As for 
Figure 5. TGFβ signalling activation decreases haematopoietic gene expression and increases EMT and 
vascular genes transcription. (A) Box plots comparing the expression of vascular specific genes between 
the control, SB431542 and TGFβ 2 conditions. (B) Box plots comparing the expression of haematopoietic 
genes between the 3 conditions. (C) Box plots comparing the expression of EMT specific genes between the 3 
conditions. The box plots were generated from 4 independent experiments. For each plot, the top and bottom 
box edges correspond to the first and third quartiles. The black line inside the box represents the median. 
The top and bottom whisker lines mark the maximum and minimum values of the data set, respectively. The 
corresponding p-values were calculated with Student’s t-test (Supplementary Table S7).
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the in vitro generated EC and Pre-HPC populations, their in vivo counterparts were the most likely to respond to 
TGFβ signalling. Fbn1, Col4a2 and Bmp4, vascular and extracellular matrix genes identified in the gene expres-
sion analysis (Figs 4 and 5), were all up-regulated upon TGFβ activation and they had a higher level of transcrip-
tion in the EC population compared to the other groups (Fig. 6D and Supplementary Table S8). We observed the 
same expression pattern with the in vitro generated populations (Supplementary Fig. S8)
TGFβ triggers the expression of markers characteristic of EMT. We checked whether or not these genes could 
be associated with the progression of blood cell formation in vivo. We examined the expression of the EMT 
related genes, Acta2, Cdh2, Serpine1, Snai1 and Snai2. Interestingly most of them were expressed at a low level 
and had a similar transcriptional level in all 3 populations. Only Cdh2 and Snai1 were expressed higher in the EC 
population compared to the other 2 (Fig. 6E and Supplementary Table S8). It showed clearly that the expression 
of these markers was not related to blood cell formation. Moreover, in the in vitro generated populations, Acta2, 
Cdh2, Serpine1 and Snai1 were all expressed higher in the EC group than in the Pre-HPC and HPC populations 
Figure 6. TGFβ pathway related genes are expressed during EHT in the Aorta Gonad Mesonephros 
(AGM) region. (A) Box plots comparing the expression of TGFβ receptors between the EC, Pre-HPC and HPC 
populations isolated from E11 AGM region. (B) Box plots comparing the expression of TGFβ ligands coding 
genes between the EC, Pre-HPC and HPC populations. (C) Box plots comparing the expression of SMAD 
coding genes in EC, Pre-HPC and HPC populations. (D) Box plots comparing the expression of vascular and 
extracellular matrix genes in EC, Pre-HPC and HPC populations. (E) Box plots comparing the expression of 
EMT specific genes in EC, Pre-HPC and HPC populations. The box plots were generated from 4 independent 
experiments. For each plot, the top and bottom box edges correspond to the first and third quartiles. The 
black line inside the box represents the median. The top and bottom whisker lines mark the maximum and 
minimum values of the data set, respectively. The corresponding p-values were calculated with Student’s t-test 
(Supplementary Table S8).
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(Supplementary Fig. S8 and Supplementary Table S1). In conclusion we showed that EMT markers are not a good 
indicator of the EHT process and that genes whose expression was up-regulated by the TGFβ treatment are more 
expressed in the endothelial lineage.
Overexpression of Sox17 during EHT partially recapitulates the effects of TGFβ signalling 
activation. Using several assays we demonstrated that TGFβ signalling activation inhibits the formation of 
blood cells. To know how TGFβ mediates this inhibition, we looked for candidate genes. We found that following 
TGFβ 2 treatment, the expression of the gene Sox17 was increased. This gene is crucial to acquire and maintain 
arterial identity38. We hypothesised that its higher expression after TGFβ treatment could maintain the expression 
of endothelial genes and therefore block EHT.
We generated a dox-inducible Sox17-mCherry ES cell (iSox17) line in which addition of dox leads to the 
overexpression of the Sox17 protein (Supplementary Fig. S9A and S9B). We then sorted Pre-HPC generated from 
the iSox17 ES cell line and cultured the cells either with or without dox. Time-lapse microscopy showed a block 
in the formation of round cells (Fig. 7A, Supplementary Fig. S9C and Supplementary Videos S5 & S6) and in fact 
the majority of the cells still maintained the Pre-HPC phenotype (VE-Cad+ CD41+) 48 hours after the treatment 
with dox (Fig. 7B,C). Next, we extracted RNA from these cells and tested by q-RT-PCR the expression of endothe-
lial and hematopoietic genes as well as the genes coding for the EMT markers. We showed that the expression of 
many endothelial genes was higher in presence of Sox17 (Fig. 7D and Supplementary Table S9). In contrast, the 
expression of Spi1 and Itgam was clearly reduced. Interestingly Runx1, Itga2b, Itgb3 and Mpo expression remained 
similar between the 2 conditions (Supplementary Fig. S9D and Supplementary Table S9). Finally the expression of 
most of the tested EMT genes did not change significantly at the exception of Acta2 (Fig. 7E and Supplementary 
Table S9).
In conclusion, we showed that the overexpression of Sox17 alone was enough to block the morphological 
changes occurring during EHT. However, we did not notice a decrease of CD41 expression and the scattered 
mesenchymal morphology observed after TGFβ treatment.
Discussion
In this work, we used gain and loss of function approaches to study the impact of TGFβ signalling on the emer-
gence of blood progenitors from endothelial cells with the model of in vitro ESC differentiation. Our working 
hypothesis was to consider that the EHT process would require similar signalling pathways as the ones involved 
in the EndMT, which occur during embryonic development and have been involved in several diseases11,12. We 
focused on the TGFβ pathway whose activity as an activator of EndMT and EMT is well documented8.
Our secretome analysis, the first one ever done on early blood development from mesodermal cells indicated 
that TGFβ treatment of BL-CFC differentiated cells for only 6 hours was enough to increase significantly the pro-
duction of proteins involved in cell migration, vascular development and cell adhesion. The increase of MMP2 
protein quantity in the extracellular space after TGFβ 2 treatment is in line with reports linking TGFβ activity 
with MMP2 secretion and induction of EMT8,29,39. However we had no evidence of an enhancement of blood cell 
formation.
We next focused on the Pre-HPC population, which is the intermediary step between EC and HPC stages. 
Time-lapse imaging and flow cytometry experiments clearly demonstrated that TGFβ 2 treatment inhibits hae-
matopoiesis. Gene expression profiling further confirmed this as there was a dramatic reduction of genes related 
to the blood lineage. Finally, we detected the up-regulation of genes related to vasculature, extracellular matrix 
and cell adhesion, which was consistent with the proteomics data. We noticed also an increase of EMT markers8. 
That showed that not only TGFβ 2 blocked haematopoiesis but also led to an EndMT process rather than EHT in 
our system.
ACVRL1 (ALK1) and TGFBR1 (ALK5) can both mediate TGFβ signalling in endothelial cells. Both receptors 
are expressed in EC and Pre-HPC (Fig. 1B). However our data suggest that the signalling through TGFBR1 is 
inhibiting blood cell formation and inducing EndMT. This is supported by a study40 showing that constitutive 
activation of ACVRL1 in EB culture increases the number of haematopoietic progenitors while a constitutive 
active form of TGFBR1 reduces haematopoietic differentiation. Whereas their work did not show exactly which 
cell type was affected by the activation of TGFBR1 activity, their results are consistent with our findings.
In line with our findings that inhibition of TFGβ signalling supports haematopoiesis, a study provided evi-
dence that SB431542 treatment promotes the generation of a higher frequency of haematopoietic progenitors 
from human pluripotent stem cells41.
To find out how TGFβ signalling activation blocks EHT, we chose to study the gene coding for the transcrip-
tion factor Sox17. It has been proposed that Sox17 is necessary for the formation of haemogenic endothelium 
in vivo42. A conditional knockout of Sox17 in endothelial cells strongly abrogates haematopoietic stem cells for-
mation in the mouse embryo42. In contrast, a recent publication by the group of Ann Zovein has shown that over-
expression of Sox17 in endothelial cells from AGM inhibits blood cell formation43. The discrepancy may come 
from the fact that Sox17 is essential for arterial specification38. Haemogenic endothelial cells are of arterial type 
and therefore need Sox17 to be produced. However once haemogenic endothelial cells are produced, Sox17 has 
to be down-regulated to enable the EHT to take place and generate blood progenitor and stem cells. Our results 
support the findings of Lizama et al.43. The overexpression of Sox17 blocked severely the morphological transition 
from endothelial to round blood cells. This was very similar to the effect of TGFβ activation. Nevertheless there 
were clear differences such as the lack of mesenchymal phenotype and the maintenance of CD41 expression. 
Apart from an increase of Acta2 gene expression, most of the EMT marker genes were not transcribed at a higher 
level when Sox17 was up-regulated. We are proposing a model by which TGFβ induces expression of endothelial 
genes such as Sox17, which can block EHT. Other unidentified factors independent of Sox17 may also play a role 
in inhibiting haematopoiesis and promoting the mesenchymal phenotype that we observed (Fig. 8).
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Overall our study suggests that the TGFβ signalling through TGFBR1 has to be tightly regulated to not inhibit 
EHT and ensure an effective production of HPC. Our q-RT-PCR data on in vivo populations involved in EHT 
showed that EC and Pre-HPC are capable to respond to TGFβ signalling through TGFBR1. Our work could 
Figure 7. Overexpression of Sox17 during EHT partially recapitulates the effect of TGFβ signalling 
activation. (A) Images of the haemogenic endothelium (HE) culture taken after 48 h in absence or presence 
of doxycycline (dox). The scale bar corresponds to 200 μ m. (B) Flow cytometry analysis of VE-Cad and 
CD41 expression after 2 days of culture in absence or presence of dox. (C) Bar graph representing the average 
frequency of the 2 indicated populations from 3 independent experiments. The p-values were calculated with 
Student’s t-test (2 tails, type 3). VE-Cad+ CD41+ population: **“No dox” versus “with Dox” p-value = 0.0002 
(n = 3); VE-Cad− CD41+ population: **“No dox” versus “with Dox” p-value = 0.0018 (n = 3). (D) Box plots 
comparing the expression of vascular specific genes between the 2 conditions. (E) Box plots comparing the 
expression of EMT specific genes between the 2 conditions. The box plots were generated from 3 independent 
experiments. For each plot, the top and bottom box edges correspond to the first and third quartiles. The 
black line inside the box represents the median. The top and bottom whisker lines mark the maximum and 
minimum values of the data set, respectively. The corresponding p-values were calculated with Student’s t-test 
(Supplementary Table S9).
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form the basis of new studies in the embryo to uncover how the TGFβ signalling affects the emergence of blood 
progenitors and stem cells.
Finally whereas our data suggest that EMT/EndMT and EHT are initiated by different processes, it would 
be worthwhile to test whether other signalling pathways involved in EMT such as EGF and PDGF pathways44,45 
could play a role in EHT.
Methods
Embryonic stem cell growth and differentiation. The Runx1+/hCD4 46, iGFP-Smad7 and iSox17-
mCherry ES cell lines were used. Growth and differentiation of ES cells were performed according to previous 
protocols47. The ES cell culture media was made of Knockout™ DMEM (Life technologies, cat. #10829-018), 15% 
FBS (PAA, cat. #A15-102), 0.0024% 1 mg/ml LIF (EMBL-Heidelberg) and 0.24% 50 mM 2-mercapto-ethanol 
(Life technologies, cat. #31350-010).
Mouse embryo generation. Timed mating of wild type C57BL/6-N mice were set up and the morning 
of vaginal plug detection was considered day 0.5. Day 11 embryos were staged by morphological landmarks. All 
experiments were performed in accordance with the guidelines and regulations defined by the European and 
Italian legislations (Directive 2010/63/EU and DLGS 26/2014, respectively). They apply to foetal forms of mam-
mals as from the last third of their normal development (from day 14 of gestation in the mouse). They do not 
cover experiments done with day 11 mouse embryos. Therefore no experimental protocol or licence was required 
for the current study. Mice were bred and maintained at EMBL Monterotondo Mouse Facility in accordance with 
European and Italian legislations (EU Directive 634/2010 and DLGS 26/2014, respectively).
Generation of doxycycline inducible ESC lines. The doxycycline-inducible GFP-Smad7 and 
Sox17-mCherry ESC lines were produced using the method of inducible cassette exchange described previ-
ously48. Briefly the GFP-Smad7 insert was excised from the pcDNA5-FRT-TO-GFP-SMAD7 plasmid while the 
Sox17-mCherry cDNA was synthesised by the GenScript Gene Synthesis Service (http://www.genscript.com/
gene_synthesis.html). Both inserts were cloned into the p2Lox plasmid and subsequently transfected in A2Lox.
cre ESC line previously treated with 0.5 μ g/mL doxycycline for one day. Selection was performed in 300 μ g/mL 
of G418 (Gibco) antibiotic for 10 days. Ten colonies were then picked and tested by flow cytometry for GFP or 
mCherry expression following a 24 h culture with and without doxycycline. The ESC clones presenting the high-
est expression level of fluorescent protein upon doxycycline induction were then chosen for further experiments.
Flow cytometry and cell sorting. Staining was done as described previously46 and analyses were per-
formed with a FACSCanto (Becton Dickinson). Sorts were performed with a FACSAria (Becton Dickinson) or 
by using magnetic sorting (Miltenyi Biotec, cat. #130-090-485) and anti-APC microbeads (Miltenyi Biotech, cat. 
#130-090-855). Monoclonal rat anti-mouse antibodies used were Anti-Mouse CD309 (FLK1) APC (Avas12a1, 
eBioscience, cat. #17-5821-81), Anti-Mouse CD41 PE (MWReg30, eBioscience, cat. #12-0411-81), Anti-Mouse 
CD144 (VE-Cadherin) eFluor® 660 (eBioBV13, eBioscience, cat. #50-1441-80). FACS data were analysed using 
the FlowJo software (Tree Star, Inc.).
BL-CFC and haemogenic endothelium cultures. Flk-1+ cells from day 3–3.25 EBs were cultured on 
gelatinized plate at a density of 0.1 × 106 cells per cm2 in the BL-CFC differentiation media containing IMDM 
supplemented with 10% FBS (PAA Clone, cat. #A15–102), 1% L-glutamine (GIBCO, cat. #25030-024), 0.6% 
30 mg/ml transferrin (Roche Diagnostics Limited, cat. #10652202001), 0.3% 0.15 M Monothioglycerol (MTG) 
(Sigma, cat. #M6145-25 ml), 0.5% 5 mg/ml ascorbic acid (Sigma, cat. #A-4544), 15% D4T conditioned medium, 
0.1% 5 μ g/ml VEGF (R&D systems, cat. #293-VE), and 0.1% 10 μ g/ml IL-6 (R&D systems, cat. #406-ML).
For haemogenic endothelium culture, FACS-sorted VE-Cad+CD41+ cells (Pre-HPC) were cultured on gelat-
inized plate at a density of 0.2 × 106 cells per cm2 (cells isolated from day 1.5 BL-CFC culture). The medium was 
composed of IMDM supplemented with 10% FBS (same as BL-CFC mix), 1% L-glutamine, 0.6% 30 mg/ml trans-
ferrin, 0.3% 0.15 M MTG, 0.5% 5 mg/ml ascorbic acid, 0.024% 100 μ g/ml LIF (EMBL-Heidelberg), 0.5% 10 μ g/
ml SCF (R&D systems, cat. #455-MC), and 0.1% 10 μ g/ml Oncostatin M (R&D systems, cat. #495-MO). Cultures 
were maintained in a humidified chamber in a normal O2 5% CO2-air mixture at 37 °C.
Figure 8. Model. The TGFβ signalling activation inhibits EHT through the up-regulation of Sox17 expression 
and the induction of EndMT.
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Quantitative RT-PCR. Two different methods were used for quantitative RT-PCR depending on the num-
ber of cells used for analysis.
For number of cells ranging from 0.1 × 106 to 1 × 106, RNA extraction was done using either the QIAGEN 
RNeasy Micro Kit (Qiagen, cat. #74004) or Qiagen RNAeasy Plus Mini kit (Qiagen, cat. #74134). The cDNA was 
synthesized using the RevertAid H minus First Strand cDNA synthesis kit (ThermoFisher Scientific, cat. #K1631). 
Random hexamer primers (0.2 μ g) were added to total RNA (500 ng), and the mix was incubated at 65 °C for 
5 min. Reaction buffer (1x), RiboLock RNase inhibitor (20U), dNTP mix and RevertAid Reverse transcriptase 
(200U) were added to the mixture and mixed gently. The reaction mix was then incubated at 25 °C for 5 min fol-
lowed by an incubation at 42 °C for 60 min. Reaction was terminated by a 70 °C incubation for 5 min. Quantitative 
PCR reactions (see Supplementary Table S10 for primer sequences) were performed with the LightCycler 480 
SYBR Green I Master kit (Roche, cat. #04707516001) and the Roche LightCycler 480 RT-PCR instrument. The 
PCR results were normalised according to the reference gene Ppia49.
For 25 cells we used a nested PCR approach with the Fluidigm Biomark HD system. Nested PCR was done for 
each gene with 2 outer primers and 2 inner primers (see Supplementary Table S11 for primer sequences) accord-
ing to the Fluidigm Advanced Development Protocol, section 41. Reagents of the CellsDirect One-Step qRT-PCR 
kit (Invitrogen cat. #11753) were used for this protocol. Twenty-five cells of EC, Pre-HPC and HPC populations 
from in vitro differentiated ESC or cells isolated from E11 AGM region were FACS-sorted in one well of 96-well 
plate (Bio-Rad Hard-Shell PCR plates cat. #HSP9611) filled with 5 μ l of 2x reaction mix (Invitrogen cat. #11753). 
The cells were snap-frozen immediately on dry ice after sort and stored at − 80 °C. RT/Specific Target amplifi-
cation (STA) was performed with a mix composed of 2.8 μ l of resuspension buffer (Invitrogen cat. #11753), 0.2 
μ l of SuperScriptIII & Platinum Taq polymerase (Invitrogen cat. #11753) and 1 μ l of 500 nM outer primer mix 
(forward and reverse primers). Four μ l of the RT-STA mix were added to the frozen cells and the RT-STA pro-
ceeded according to the following steps. The RT were done with a 50 °C incubation for 15 minutes, followed by 
inactivation at 95 °C for 2 minutes. Then the STA reaction were performed at 95 °C for 15 seconds and 60 °C for 
4 minutes for 20 cycles. The cDNA within each well was diluted 1/5 and the sample mix was prepared with load-
ing reagent (Fluidigm) and SsoFast™ EvaGreen® Supermix (Bio-Rad). In parallel individual assay mixes were 
prepared as 5 μ M inner primer mix, with DNA suspension buffer and assay loading reagent. After the priming of 
96.96 dynamic array IFC (Fluidigm, cat. #BMK-M-96.96), the sample mix and assay mixes were put together in 
the corresponding inlets and loaded into the chip. Finally the chip was run in the Biomark by using the Biomark 
Data Collection Software and the GE96 × 96PCR+ Meltv2.pcl program. Raw data were opened and analysed with 
the Fluidigm Real Time PCR Analysis software. For each primer, Ct values and melting curves could be visual-
ized. The raw data were analysed with the following options: quality threshold set at 0.65, Ct threshold was Auto 
(Global), and baseline correction method was linear (derivative). The whole experiment was performed 3 to 4 
times. The PCR results were normalised according to the reference gene Ppia.
Quantitative RT-PCR expression results were displayed as box plots with the function boxplot in R (http://
www.r-project.org).
Activation and inhibition of the TGFβ pathway. To activate the TGFβ pathway, the recombinant 
mouse TGFβ 2 (R&D systems, cat. #7346-B2, re-suspended in 4 mM HCl+ 0.1% BSA 1X PBS) was added into 
the culture medium at 5 ng/ml final concentration. The inhibition of the TGFβ pathway was performed using 
SB431542 (Tocris, cat. #1614, re-suspended in DMSO) at 10μ M final concentration. Vehicle controls for TGFβ 2 
and SB431542 were the same volumes of 4 mM HCl+ 0.1% BSA 1X PBS and DMSO, respectively.
Proteomics analysis of secreted proteins. After 24 hours of BL-CFC culture the medium was removed 
and cells were washed with pre-warmed 1X PBS twice. Then they were incubated with an adapted BL-CFC culture 
medium made of DMEM depleted of methionine, arginine and lysine (Gibco) and 10% dialyzed FBS (Gibco) 
which was supplemented with 0.1 mM L-AHA (AnaSpec, Inc) and either 84 μ g/ml [13C6] L-arginine and 146 
μ g/ml [d4] L-lysine or 84 μ g/ml [13C6 15N4] L-arginine and 146 μ g/ml [13C6 15N2] L-lysine (Cambridge Isotope 
Laboratories, Inc). Cells were treated either with TGFβ 2 or vehicle control for 6 hours. The supernatant was taken, 
spun to remove floating cells and frozen on dry ice. The enrichment of newly made proteins, LC-MS/MS and data 
analysis were performed as described22. A total of 3 independent experiments were performed. Visual representa-
tion of identified proteins and gene ontology analysis were done with STRING 10 (http://string-db.org)23.
Time-lapse photography. The phase contrast time-lapse images were taken with the IncuCyte HD (Essen 
Biosciences) inside an incubator, every 15 minutes, 9 areas per well. The time-lapse videos have 10 frames per 
second. They were made with the Fiji software (http://fiji.sc/Fiji). The images from each area were analysed by the 
Cell Profiler software (http://www.cellprofiler.org) to quantify the number of round cells in each frame with a cus-
tomized pipeline written by Christian Tischer from the EMBL Heidelberg Advanced Light Microscopy Facility. 
For each time point, the average and standard deviation of counts from all 9 spots were calculated to make graph 
with Microsoft Office Excel software.
mRNA microarray. Total RNA extracted with Qiagen RNAeasy Plus Mini kit (Qiagen, cat. #74134) was 
tested for its quality with BioAnalyzer (Agilent) and its concentration measured using Qubit (Life Technologies). 
The samples were hybridised on Affymetrix GeneChip Mouse Gene 2.0 ST Array. Data were analysed using R 
with the packages limma, oligo, pvclust, genefilter and pd.mogene.2.0.st. Gene Ontology studies were performed 
with the Database for Annotation, Visualization and Integrated Discovery (DAVID) tool (http://david.abcc.ncif-
crf.gov).
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